Although HER2 positive cancer was detected at all three tumor locations we analyzed the immune features of HER2 postive cancers as well and observed that HER2 positivity is associated with a significantly higher percentage of CD163+CD14+ conventional Dendritic cells (cDC) and CD4+ T cells, and less Ki67+ CD4 Th cells and Ki67+ CD8 cells compared to HER2 negative tumors (Figure 1C; Supplementary Table 9). The gene discussed is CD163; the disease is cancer.